Prairiewood Capital’s Medifast MED Stock Holding History

Prairiewood Capital’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,215	Closed	-$276K	–	83
2024 Q1	$276K	Buy	7,215 +1,520	+27%	+$73.6K	0.13%	69
2023 Q4	$383K	Buy	5,695 +2	+0%	+$139	0.2%	65
2023 Q3	$426K	Buy	5,693 +62	+1%	+$5.5K	0.28%	57
2023 Q2	$519K	Buy	5,631 +1,134	+25%	+$101K	0.35%	51
2023 Q1	$466K	Buy	4,497 +726	+19%	+$80.5K	0.32%	54
2022 Q4	$435K	Buy	3,771 +2	+0.1%	+$233	0.32%	54
2022 Q3	$408K	Buy	3,769 +838	+29%	+$120K	0.34%	56
2022 Q2	$529K	Hold	2,931	–	–	0.42%	44
2022 Q1	$501K	Buy	2,931 +1,841	+169%	+$347K	0.35%	50
2021 Q4	$228K	Hold	1,090	–	–	0.18%	67
2021 Q3	$210K	Hold	1,090	–	–	0.17%	67
2021 Q2	$308K	Sell	1,090 -3,372	-76%	-$914K	0.26%	61
2021 Q1	$945K	Hold	4,462	–	–	0.87%	36
2020 Q4	$876K	Buy	+4,462	New	+$789K	0.89%	34

Other funds holding MED

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Prairiewood Capital's MED Position: Q2 2024 in Review

Prairiewood Capital sold out of Medifast (MED) in Q2 2024, closing a stake of 7,215 shares — an estimated $276K sold.

Prairiewood Capital first reported a position in MED in Q4 2020 and held it in 14 quarters. The position peaked at $945K in Q1 2021. 158 funds tracked by Wall St. Rank hold MED as of Q2 2024.

Prairiewood Capital reported no remaining Medifast position as of Q2 2024 after selling out during the quarter.
Prairiewood Capital sold 7,215 Medifast shares in Q2 2024, an estimated $276K.
Prairiewood Capital first reported a position in Medifast in Q4 2020 and held it in 14 quarters.
Prairiewood Capital's Medifast position peaked at $945K in Q1 2021.
158 funds tracked by Wall St. Rank held Medifast as of Q2 2024.

Based on Prairiewood Capital's 13F filing for Q2 2024, filed 18 Jul 2024.